Ultromics, an Oxford, UK-based company focused on advancing AI enabled cardiovascular imaging solutions, raised $33M in series B funding.
The round was led by Blue Venture Fund with participation from Optum Ventures, GV and Oxford Sciences Innovation.
The company intends to use the funds to accelerate the use of AI-enabled echocardiograms to improve patient care, and bring improved diagnostic quality and resource savings to hospitals.
Led by Dr. Ross Upton, Ultromics provides automated software powered by AI that allows clinicians to make fast, accurate decisions when using ultrasound images to diagnose cardiovascular disease. The EchoGo Core and EchoGo Pro platforms deliver accurate assessments of heart function that support the diagnosis of coronary artery disease, heart failure and amyloidosis. Both spun out of the University of Oxford and built-in partnership with the U.K.’s National Health Service (NHS), EchoGo Core and EchoGo Pro are already being used and validated by several organizations, including Mayo Clinic and the Oregon Health and Science University.